These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 7497586

  • 1. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M.
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL.
    Cancer Res; 1991 Nov 15; 51(22):6059-65. PubMed ID: 1933869
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD, Spaander M, Mathĵt RA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S.
    Ann Oncol; 2002 Mar 15; 13(3):374-84. PubMed ID: 11996467
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma.
    Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, Kitagawa H, Noda N, Sugimoto S, Hara J.
    Cancer Chemother Pharmacol; 2019 Oct 15; 84(4):849-860. PubMed ID: 31428821
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
    Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD.
    Ther Drug Monit; 2009 Feb 15; 31(1):95-103. PubMed ID: 19155964
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.
    Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J.
    J Natl Cancer Inst; 1988 Oct 05; 80(15):1221-6. PubMed ID: 3138431
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T.
    Bone Marrow Transplant; 1994 Nov 05; 14(5):813-9. PubMed ID: 7889015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.